Claudia Cruz Sequeiros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudia Cruz Sequeiros has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Jesús González-Barboteo
Department of Palliative Care, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain
2 shared publications - Maria Labori Trias
Department of Palliative Care, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain
2 shared publications Pierluigi Bavestrello
Department of Palliative Care, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain
2 shared publications- Silvia Llorens Torromé
Palliative Care Service, Catalan Institute of Oncology (ICO, IDIBELL) (C.C.S., S.L.T., G.S.B.), Hospital Duran i Reynals, Barcelona, Spain
2 shared publications - Agnès Calsina-Berna
Institut Català d'Oncologia-Badalona
1 shared publication - Anna Casellas-Grau
Institut Català d'Oncologia, Barcelona, Spain
1 shared publication
Latest Publications
- 14 July 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (9) , 1394-1399
Integration of palliative care in a multidisciplinary head and neck cancer clinic: A prospective cohort study
Background: Integrated palliative care may improve outcomes in patients with cancer, but few studies have specifically evaluated its benefits in head and neck cancer. Aim: To assess changes in symptom control, quality of life, and supportive care needs in patients with head and neck cancer consecutively treated at a palliative care outpatient clinic over 12 months. Design: Prospective cohort study. Symptoms were assessed at baseline and at 1.5, 3, 6, 9, and 12 months, and quality of life at baseline, 2, and 4 months. Symptom management was adjusted and referrals made as needed. Setting and participants: Palliative care outpatient clinic integrated into the head and neck cancer unit of a comprehensive cancer center. Patients with head and neck cancer referred to this clinic who attended their first consultation were eligible. Results: 118 patients (69.5% males; mean [SD] age 62.9 [10.5] years) were included. Most (91%) had active disease (85% receiving anti-cancer treatment). From baseline to month 12, improvements were observed in: average pain intensity (mean [95% CI]), 2.53 [2.09; 2.96] to 1.5 [0.86; 2.14]; total symptom distress score, 27.96 [25.35; 30.57] to 20.34 [16.63; 24.05]; anxiety, 1.86 [1.48; 2.24] to 1.14 [0.57; 1.7]; depression, 3.46 [3; 3.93] to 2.79 [2.13; 3.45]. Quality of life improved from baseline to month 4. Referral rates to supportive care were: social work (50%), psycho-oncology (21%), psychiatry (12%). Conclusions: Patients managed at a dedicated palliative care outpatient clinic showed improvements in symptom control and quality of life over time, which may reflect the contribution of integrated palliative care in the ambulatory setting.
- 14 July 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (9) , 1394-1399
Integration of palliative care in a multidisciplinary head and neck cancer clinic: A prospective cohort study
Background: Integrated palliative care may improve outcomes in patients with cancer, but few studies have specifically evaluated its benefits in head and neck cancer. Aim: To assess changes in symptom control, quality of life, and supportive care needs in patients with head and neck cancer consecutively treated at a palliative care outpatient clinic over 12 months. Design: Prospective cohort study. Symptoms were assessed at baseline and at 1.5, 3, 6, 9, and 12 months, and quality of life at baseline, 2, and 4 months. Symptom management was adjusted and referrals made as needed. Setting and participants: Palliative care outpatient clinic integrated into the head and neck cancer unit of a comprehensive cancer center. Patients with head and neck cancer referred to this clinic who attended their first consultation were eligible. Results: 118 patients (69.5% males; mean [SD] age 62.9 [10.5] years) were included. Most (91%) had active disease (85% receiving anti-cancer treatment). From baseline to month 12, improvements were observed in: average pain intensity (mean [95% CI]), 2.53 [2.09; 2.96] to 1.5 [0.86; 2.14]; total symptom distress score, 27.96 [25.35; 30.57] to 20.34 [16.63; 24.05]; anxiety, 1.86 [1.48; 2.24] to 1.14 [0.57; 1.7]; depression, 3.46 [3; 3.93] to 2.79 [2.13; 3.45]. Quality of life improved from baseline to month 4. Referral rates to supportive care were: social work (50%), psycho-oncology (21%), psychiatry (12%). Conclusions: Patients managed at a dedicated palliative care outpatient clinic showed improvements in symptom control and quality of life over time, which may reflect the contribution of integrated palliative care in the ambulatory setting.
- Open Access
- 9 February 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (5) , 685-697
Early Supportive Versus Standard Care in Phase I Cancer Trials: A Randomized Controlled Trial
- 9 February 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (5) , 685-697
Open AccessEarly Supportive Versus Standard Care in Phase I Cancer Trials: A Randomized Controlled Trial
- 11 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 83
Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study
Purpose To describe the frequency of opioid-induced neurotoxicity (OINT) after opioid conversion (OC) to methadone using the Stop-and-Go (SAG) method in cancer patients with inadequate pain control, and to identify factors associated with OINT. Methods This multicenter retrospective cohort study included adult hospitalized cancer patients who underwent OC to methadone using the SAG method for poor pain control at two comprehensive cancer centers between January 2018 and October 2022. Patients were monitored 14 days after OC, and variables related to OINT were analyzed. Ethical approval was obtained. Results A total of 372 patients underwent OC using the SAG method. The mean morphine-equivalent daily dose (MEDD) before OC was 212.2 mg (SD 128). OINT occurred in 70 patients (18.8%). Methadone was permanently discontinued in 2 patients (2.8%) and temporarily withheld in 7, while 61 were managed with hydration and a 15–20% methadone dose reduction. No patient required naloxone. OINT was less frequent in younger patients (mean age 59.4 vs. 63 years; p = 0.032) and showed a trend toward lower incidence in women (13% vs.22%; p = 0.065). Preexisting cognitive impairment or delirium was associated with OINT (52.4% vs.16.8%; p < 0.001). The mean time from OC to death was shorter among patients with OINT (2.1 months; SD 3.9) compared with those without OINT (3.6 months; SD 6.4; p = 0.012). Conclusion OC to methadone using the SAG method in patients with low-to-moderate MEDD was associated with a relatively low OINT frequency (18.8%). These findings suggest that SAG method in patients with low-to-moderate MEDD before OC may be safe, particularly for younger patients and those without cognitive impairment.
- 11 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 83
Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study
Purpose To describe the frequency of opioid-induced neurotoxicity (OINT) after opioid conversion (OC) to methadone using the Stop-and-Go (SAG) method in cancer patients with inadequate pain control, and to identify factors associated with OINT. Methods This multicenter retrospective cohort study included adult hospitalized cancer patients who underwent OC to methadone using the SAG method for poor pain control at two comprehensive cancer centers between January 2018 and October 2022. Patients were monitored 14 days after OC, and variables related to OINT were analyzed. Ethical approval was obtained. Results A total of 372 patients underwent OC using the SAG method. The mean morphine-equivalent daily dose (MEDD) before OC was 212.2 mg (SD 128). OINT occurred in 70 patients (18.8%). Methadone was permanently discontinued in 2 patients (2.8%) and temporarily withheld in 7, while 61 were managed with hydration and a 15–20% methadone dose reduction. No patient required naloxone. OINT was less frequent in younger patients (mean age 59.4 vs. 63 years; p = 0.032) and showed a trend toward lower incidence in women (13% vs.22%; p = 0.065). Preexisting cognitive impairment or delirium was associated with OINT (52.4% vs.16.8%; p < 0.001). The mean time from OC to death was shorter among patients with OINT (2.1 months; SD 3.9) compared with those without OINT (3.6 months; SD 6.4; p = 0.012). Conclusion OC to methadone using the SAG method in patients with low-to-moderate MEDD was associated with a relatively low OINT frequency (18.8%). These findings suggest that SAG method in patients with low-to-moderate MEDD before OC may be safe, particularly for younger patients and those without cognitive impairment.